Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News

    Latest News - Page 225

    AstraZeneca plots China robot offensive to counter price cuts

    AstraZeneca plots China robot offensive to counter price cuts

    Medical Dialogues Bureau21 Sept 2018 9:02 AM IST
    WUXI, China/LONDON: With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest...
    EU approves fifth copy of AbbVie

    EU approves fifth copy of AbbVie's $18 Billion drug Humira

    Medical Dialogues Bureau21 Sept 2018 9:00 AM IST
    LONDON: Europe has approved a fifth copy of AbbVie's $18-billion-a-year biologic drug Humira - the world's best-selling prescription medicine -...
    Paras Healthcare appoints Devendra Kumar Punia as Corporate Head - IT

    Paras Healthcare appoints Devendra Kumar Punia as Corporate Head - IT

    Medical Dialogues Bureau20 Sept 2018 3:17 PM IST
    In this new journey as Head- IT in Paras healthcare group, my strengths and responsibilities will rely on leveraging more data resources to deliver...
    California: Drugmaker paid doctors to overprescribe Humira

    California: Drugmaker paid doctors to overprescribe Humira

    Medical Dialogues Bureau20 Sept 2018 1:52 PM IST
    Pharmaceutical giant AbbVie illegally plied doctors with cash, gifts, and services to prescribe one of the world's best-selling drugs, Humira, despite...
    Biopharmaceutical company fined for misleading investors

    Biopharmaceutical company fined for misleading investors

    Medical Dialogues Bureau20 Sept 2018 1:48 PM IST
    BOULDER, Colo. - A Colorado-based biopharmaceutical company has been penalized more than $20 million for misleading investors about the efficacy of a...
    Bayer Monsan to asks U.S. court to toss $289 mln glyphosate verdict

    Bayer Monsan to asks U.S. court to toss $289 mln glyphosate verdict

    Medical Dialogues Bureau20 Sept 2018 1:47 PM IST
    US- Bayer AG unit Monsanto asked a California judge to throw out a $289 million jury verdict awarded to a man who alleged the company's...
    GSK grabs new drug development head from Boehringer

    GSK grabs new drug development head from Boehringer

    Medical Dialogues Bureau20 Sept 2018 9:46 AM IST
    LONDON: GlaxoSmithKline has hired Chris Corsico from German drugmaker Boehringer Ingelheim to fill the new role of senior vice-president development...
    Glenmark Pharma finds way into Dow Jones Sustainability Indices

    Glenmark Pharma finds way into Dow Jones Sustainability Indices

    Medical Dialogues Bureau19 Sept 2018 4:02 PM IST
    Glenmark Pharmaceuticals inducted into the Dow Jones Sustainability Indices (DJSI) Emerging Market 2018, one of the most prestigious global...
    Sun Pharma Gets European approval for Ilumetri to treat Psoiasis

    Sun Pharma Gets European approval for Ilumetri to treat Psoiasis

    Medical Dialogues Bureau19 Sept 2018 4:00 PM IST
    Mumbai: Sun Pharma has recently announced that Almirall has received the European Commission (EC) approval for the treatment of adults with...
    Ugandan unit of Cipla raises $43.8 mln in IPO - Renaissance Capital

    Ugandan unit of Cipla raises $43.8 mln in IPO - Renaissance Capital

    Medical Dialogues Bureau19 Sept 2018 11:40 AM IST
    Cipla Quality Chemical Industries Ltd (CQCIL), majority owned by India's third-largest drugmaker, sold 657 million shares equivalent to 18 per cent of...
    Strides Pharma gets 3 observations from USFDA for Bangalore plant

    Strides Pharma gets 3 observations from USFDA for Bangalore plant

    Medical Dialogues Bureau19 Sept 2018 9:36 AM IST
    The company believes that the observations are not material in nature and have already responded to the USFDA, it added.New Delhi: Drug firm Strides...
    Aurobindo Pharma gets nod for for fixed dose triple combination for HIV

    Aurobindo Pharma gets nod for for fixed dose triple combination for HIV

    Medical Dialogues Bureau18 Sept 2018 2:34 PM IST
    Aurobindo Pharma has received approval from SAHPRA and tentative approval from USFDA for the Dolutegravir, Lamivudine and Tenofovir Disoproxil...
    PrevNext

    Popular Stories

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    CDSCO bans OTC sale of topical medications containing hydroquinone from April 1, 2019

    CDSCO bans OTC sale of topical medications containing hydroquinone from April 1, 2019

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

    Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

    Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

    Shipment of  antimalarial drug to US is likely to start next week: Indian Pharmaceutical Alliance

    Shipment of antimalarial drug to US is likely to start next week: Indian Pharmaceutical Alliance

    Hydroxychloroquine not approved as anti-malarial drug in India, says Ipca Laboratories Joint MD

    Hydroxychloroquine not approved as anti-malarial drug in India, says Ipca Laboratories Joint MD

    Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

    Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok